Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZYNE
CUSIPN/A
Phone484-581-7505
Debt
Debt-to-Equity RatioN/A
Current Ratio6.51
Quick Ratio6.51
Price-To-Earnings
Trailing P/E Ratio-4.03
Forward P/E Ratio-3.42
P/E GrowthN/A
Sales & Book Value
Annual Sales$10,000.00
Price / Sales13,993.92
Cash FlowN/A
Price / CashN/A
Book Value$4.50 per share
Price / Book2.29
Profitability
EPS (Most Recent Fiscal Year)($2.48)
Net Income$-32,010,000.00
Net MarginsN/A
Return on Equity-59.98%
Return on Assets-52.73%
Miscellaneous
Employees22
Outstanding Shares13,560,000
Market Cap$130.46
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions
What is Zynerba Pharmaceuticals' stock symbol?
Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."
How were Zynerba Pharmaceuticals' earnings last quarter?
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.91) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.68) by $0.23. View Zynerba Pharmaceuticals' Earnings History.
What price target have analysts set for ZYNE?
11 brokers have issued 12 month target prices for Zynerba Pharmaceuticals' stock. Their predictions range from $7.00 to $32.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $18.45 in the next twelve months. This suggests a possible upside of 83.0% from the stock's current price. View Analyst Ratings for Zynerba Pharmaceuticals.
What is the consensus analysts' recommendation for Zynerba Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?
Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
- 1. Canaccord Genuity analysts commented, "We maintain our BUY rating on KMPH shares given what we see as a potentially positive product profile for KP415 once all the data kinks are worked out. We’d be buyers on any KMPH weakness on this data read." (7/5/2018)
- 2. HC Wainwright analysts commented, "We do not see this as a material negative, as we never included ZYN001 for Tourette’s or any other indication in our estimates or valuation. Our valuation is entirely based on Orphan Designated ZYN002 transdermal cannabidiol (CBD) gel for Fragile X Syndrome (FXS), entering Phase 3 shortly, with upside optionality from ongoing work in refractory and rare epilepsies. In fact, we view this early-stage ZYN001 termination as a sign of responsible drug development and note that it actually undermines the most cynical ZYN002 bear-argument we’ve heard: that the CBD doesn’t even get into the blood. Zynerba has not released ZYN002 PK data for intellectual property reasons in a competitive CBD field, but this news should mollify investor paranoia that the company would or could have proceeded to Phase 2, let alone Phase 3, in FXS or epilepsy without foundational PK data." (7/5/2018)
- 3. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (3/15/2018)
- 4. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)
Who are some of Zynerba Pharmaceuticals' key competitors?
Some companies that are related to Zynerba Pharmaceuticals include Arcus Biosciences (RCUS), Depomed (DEPO), ArQule (ARQL), Aurinia Pharmaceuticals (AUPH), ZEALAND PHARMA/S (ZEAL), Cytokinetics (CYTK), Lannett (LCI), Verastem (VSTM), Zymeworks (ZYME), Stemline Therapeutics (STML), Synergy Pharmaceuticals (SGYP), Forty Seven (FTSV), Verrica Pharmaceuticals (VRCA), Rigel Pharmaceuticals (RIGL) and Unum Therapeutics (UMRX).
Who are Zynerba Pharmaceuticals' key executives?
Zynerba Pharmaceuticals' management team includes the folowing people:
- Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 60)
- Ms. Terri B. Sebree, Pres (Age 60)
- Mr. James E. Fickenscher, CFO & VP of Corp. Devel. (Age 54)
- Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 49)
- Ms. Suzanne M. Hanlon, Sec., VP of HR & Gen. Counsel (Age 61)
When did Zynerba Pharmaceuticals IPO?
(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.
Has Zynerba Pharmaceuticals been receiving favorable news coverage?
Media stories about ZYNE stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a news impact score of 0.15 on Accern's scale. They also gave media headlines about the company an impact score of 45.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Zynerba Pharmaceuticals' major shareholders?
Zynerba Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Pennsylvania Trust Co (1.27%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.
Which major investors are selling Zynerba Pharmaceuticals stock?
How do I buy shares of Zynerba Pharmaceuticals?
Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zynerba Pharmaceuticals' stock price today?
One share of ZYNE stock can currently be purchased for approximately $10.08.
How big of a company is Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals has a market capitalization of $130.46 million and generates $10,000.00 in revenue each year. The company earns $-32,010,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Zynerba Pharmaceuticals employs 22 workers across the globe.
How can I contact Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]
MarketBeat Community Rating for Zynerba Pharmaceuticals (NASDAQ ZYNE)
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
